Aileron Therapeutics to Present at Upcoming Investor Conferences
January 04, 2022 08:45 ET
|
Aileron Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
December 20, 2021 10:56 ET
|
Aileron Therapeutics, Inc.
BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a...
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 12, 2021 07:50 ET
|
Aileron Therapeutics, Inc.
Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned...
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
October 07, 2021 09:22 ET
|
Aileron Therapeutics, Inc.
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s...
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
September 30, 2021 16:30 ET
|
Aileron Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
September 16, 2021 08:15 ET
|
Aileron Therapeutics, Inc.
Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and...
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
September 10, 2021 08:30 ET
|
Aileron Therapeutics, Inc.
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic...
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
September 07, 2021 16:05 ET
|
Aileron Therapeutics, Inc.
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
August 27, 2021 07:45 ET
|
Aileron Therapeutics, Inc.
Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal...
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 16:20 ET
|
Aileron Therapeutics, Inc.
Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end...